| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.29 | 8e-09 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | 0.16 | 6e-07 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.16 | 6e-07 |
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-06 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-06 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-06 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.15 | 3e-06 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | 0.16 | 5e-06 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | 0.14 | 8e-06 |
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.16 | 8e-06 |